Switch theme
Sign up to access all valuation multiples
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).
2015
41
LTM Revenue $7.4M
LTM EBITDA n/a
$55.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Surrozen has a last 12-month revenue of $7.4M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Surrozen achieved revenue of $10.7M and an EBITDA of -$24.1M.
Surrozen expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Surrozen valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | $10.7M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$41.1M | -$24.1M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -226% | XXX | XXX | XXX |
| Net Profit | -$36.0M | -$43.0M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -404% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 22, 2025, Surrozen's stock price is $10.
Surrozen has current market cap of $81.5M, and EV of $55.5M.
See Surrozen trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $55.5M | $81.5M | XXX | XXX | XXX | XXX | $-16.32 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 22, 2025, Surrozen has market cap of $81.5M and EV of $55.5M.
Surrozen's trades at 7.5x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Surrozen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Surrozen and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $55.5M | XXX | XXX | XXX |
| EV/Revenue | 5.2x | XXX | XXX | XXX |
| EV/EBITDA | -2.3x | XXX | XXX | XXX |
| P/E | -1.3x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -3.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpSurrozen's NTM/LTM revenue growth is -100%
Surrozen's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.9M for the same period.
Over next 12 months, Surrozen's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Surrozen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Surrozen and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | Infinity% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -226% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -41% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.9M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 141% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 198% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 340% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Surrozen acquired XXX companies to date.
Last acquisition by Surrozen was XXXXXXXX, XXXXX XXXXX XXXXXX . Surrozen acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Surrozen founded? | Surrozen was founded in 2015. |
| Where is Surrozen headquartered? | Surrozen is headquartered in United States of America. |
| How many employees does Surrozen have? | As of today, Surrozen has 41 employees. |
| Who is the CEO of Surrozen? | Surrozen's CEO is Mr. Craig C. Parker. |
| Is Surrozen publicy listed? | Yes, Surrozen is a public company listed on NAS. |
| What is the stock symbol of Surrozen? | Surrozen trades under SRZN ticker. |
| When did Surrozen go public? | Surrozen went public in 2021. |
| Who are competitors of Surrozen? | Similar companies to Surrozen include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Surrozen? | Surrozen's current market cap is $81.5M |
| What is the current revenue of Surrozen? | Surrozen's last 12-month revenue is $7.4M. |
| What is the current EV/Revenue multiple of Surrozen? | Current revenue multiple of Surrozen is 7.5x. |
| Is Surrozen profitable? | Yes, Surrozen is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
